MEMBER NEWS: SGS joins oxford university consortium led by the Jenner Institute to develop COVID-19 vaccine

In a consortium led by the Jenner Institute, Oxford University, SGS has joined forces with specialists in infectious diseases, research and innovation, and pharmaceuticals to rapidly develop, scale-up and produce a potential vaccine called ChAdOx1 nCov-19.

With many concluding that a vaccine is the only way of safely and effectively unlocking the world from this pandemic, the COVID-19 Oxford Vaccine Trial could provide that crucial vaccine.

This work is funded by the Rapid Research Response initiative set up by UK Research and Innovation, and by the Department of Health and Social Care through the National Institute for Health Research and the Oxford Biomedical Research Centre. The study has also received financial support from the Coalition for Epidemic Preparedness Innovations and the Chinese Academy of Medical Sciences’ Innovation Fund.

The University of Oxford highlighted that preclinical testing of the ChAdOx1 nCoV-19 vaccine is being conducted, and development and scale-up of manufacturing to produce millions of doses is being carried out by the University of Oxford, the Vaccine Manufacturing and Innovation Centre (Oxford) and other partners. Already, researchers have started screening healthy volunteers (aged 18-55) for the upcoming vaccine trial in the Thames Valley Region.

Click here to read the full article.

For more information, please contact:

Dr. Archie Lovatt
Scientific Operations Director (Biosafety), SGS
t: +44 (0) 141 952 0022


SGS is the world’s leading inspection, verification, testing and certification company. SGS is recognized as the global benchmark for quality and integrity. With more than 94,000 employees, SGS operates a network of over 2,600 offices and laboratories around the world.